IRON (Disc Medicine) 1-Year Sharpe Ratio : 0.44 (As of Jul. 24, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Disc Medicine 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-07-24), Disc Medicine's 1-Year Sharpe Ratio is 0.44.

Competitive Comparison of Disc Medicine's 1-Year Sharpe Ratio

For the Biotechnology subindustry, Disc Medicine's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Disc Medicine's 1-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Disc Medicine's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Disc Medicine's 1-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

Disc Medicine 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Disc Medicine (NAS:IRON) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Disc Medicine 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Disc Medicine's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Disc Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Disc Medicine Inc (NAS:IRON) » Definitions » 1-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472

Website

https://www.discmedicine.com

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Executives

William Jacob Savage	officer: Chief Medical Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mona Ashiya	director, 10 percent owner	C/O SIERRA ONCOLOGY, INC., 2150 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA Z4 V6C 3E8
Rahul Khara	officer: General Counsel	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Jonathan Yen-wen Yu	officer: Chief Business Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
John D Quisel	director, officer: Chief Executive Officer	128 SIDNEY STREET, CAMBRIDGE MA 02139
William Richard White	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Kevin Bitterman	director	C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Joanne Bryce	officer: Chief Financial Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Brian Richard Macdonald	officer: Chief Innovation Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Ai Dmi Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Atlas Venture Associates X, Llc	10 percent owner	400 TECH. SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139